On Friday, TD Cowen maintained a Hold rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX), as the stock experiences significant pressure with a 17.35% decline over the past week.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

AbbVie, Thermo Fisher Scientific, Recursion Pharmaceuticals, Bloom Energy, and Iovance Biotherapeutics are the five Biotech ...

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and ...

Full Year 2024 Results Key Financial Results Revenue: US$58.8m (up 32% ...

On Friday, TD Cowen maintained a Hold rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX), as the stock experiences significant pressure with a 17.35% decline over the past week. According to ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and ...

EST Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals (RXRX) todayDiscover the Best Stocks and Maximize Your ...